Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Amir Tahmasb Fathi, M.D.

Co-Author

This page shows the publications co-authored by Amir Fathi and Andrew Brunner.
Connection Strength

10.084
  1. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
    View in: PubMed
    Score: 0.907
  2. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549.
    View in: PubMed
    Score: 0.842
  3. Clustered incidence of adult acute promyelocytic leukemia. Leuk Res. 2018 11; 74:47-50.
    View in: PubMed
    Score: 0.833
  4. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017 Oct 24; 1(23):2032-2040.
    View in: PubMed
    Score: 0.781
  5. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma. 2016 May; 57(5):1197-200.
    View in: PubMed
    Score: 0.672
  6. Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res. 2014 Jul; 38(7):773-80.
    View in: PubMed
    Score: 0.612
  7. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013 Aug; 88(8):642-6.
    View in: PubMed
    Score: 0.577
  8. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013 Jul 15; 119(14):2620-9.
    View in: PubMed
    Score: 0.573
  9. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis. Clin Lymphoma Myeloma Leuk. 2020 Nov; 20(11):e883-e889.
    View in: PubMed
    Score: 0.235
  10. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. Cancer. 2020 03 15; 126(6):1264-1273.
    View in: PubMed
    Score: 0.227
  11. Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. Leuk Lymphoma. 2019 12; 60(12):3058-3062.
    View in: PubMed
    Score: 0.218
  12. Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. Am J Hematol. 2018 09; 93(9):1119-1126.
    View in: PubMed
    Score: 0.207
  13. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Onco Targets Ther. 2018; 11:3425-3434.
    View in: PubMed
    Score: 0.204
  14. Incident adverse events following therapy for acute promyelocytic leukemia. Leuk Res Rep. 2018; 9:79-83.
    View in: PubMed
    Score: 0.203
  15. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018 01 15; 124(2):306-314.
    View in: PubMed
    Score: 0.195
  16. Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):988-991.
    View in: PubMed
    Score: 0.193
  17. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. Cancer. 2017 Jul 01; 123(13):2561-2569.
    View in: PubMed
    Score: 0.189
  18. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions. Pharmacol Ther. 2017 Sep; 177:123-128.
    View in: PubMed
    Score: 0.187
  19. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017 04; 102(4):719-727.
    View in: PubMed
    Score: 0.185
  20. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
    View in: PubMed
    Score: 0.179
  21. Life after transplant: are we becoming high maintenance in AML? Bone Marrow Transplant. 2016 Nov; 51(11):1423-1430.
    View in: PubMed
    Score: 0.178
  22. Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. Leuk Res Rep. 2015; 4(1):28-30.
    View in: PubMed
    Score: 0.164
  23. Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis. Leuk Lymphoma. 2015 Jun; 56(6):1698-703.
    View in: PubMed
    Score: 0.158
  24. New molecular abnormalities and clonal architecture in AML: from reciprocal translocations to whole-genome sequencing. Am Soc Clin Oncol Educ Book. 2014; e334-40.
    View in: PubMed
    Score: 0.150
  25. Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. Blood. 2021 Apr 28.
    View in: PubMed
    Score: 0.062
  26. Posttraumatic stress disorder (PTSD) symptoms in patients with acute myeloid leukemia (AML). Cancer. 2021 Mar 25.
    View in: PubMed
    Score: 0.062
  27. Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2021 Feb 01; 7(2):238-245.
    View in: PubMed
    Score: 0.061
  28. Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia. 2020 11; 34(11):3050-3054.
    View in: PubMed
    Score: 0.059
  29. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv. 2020 07 14; 4(13):3136-3140.
    View in: PubMed
    Score: 0.059
  30. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 12; 34(12):3149-3160.
    View in: PubMed
    Score: 0.058
  31. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma. 2020 05; 61(5):1220-1225.
    View in: PubMed
    Score: 0.058
  32. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 01 14; 4(1):106-111.
    View in: PubMed
    Score: 0.057
  33. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852.
    View in: PubMed
    Score: 0.055
  34. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687.
    View in: PubMed
    Score: 0.055
  35. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402.
    View in: PubMed
    Score: 0.054
  36. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254.
    View in: PubMed
    Score: 0.052
  37. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 07 24; 2(14):1765-1772.
    View in: PubMed
    Score: 0.051
  38. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
    View in: PubMed
    Score: 0.051
  39. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 04 24; 2(8):923-932.
    View in: PubMed
    Score: 0.051
  40. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biol Blood Marrow Transplant. 2018 08; 24(8):1754-1758.
    View in: PubMed
    Score: 0.050
  41. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol. 2017 12 01; 3(12):1675-1682.
    View in: PubMed
    Score: 0.049
  42. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
    View in: PubMed
    Score: 0.049
  43. Acute Leukemia is Associated with Cardiac Alterations before Chemotherapy. J Am Soc Echocardiogr. 2017 Nov; 30(11):1111-1118.
    View in: PubMed
    Score: 0.049
  44. Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation. Am J Clin Pathol. 2017 Jan 01; 147(1):50-59.
    View in: PubMed
    Score: 0.046
  45. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn. 2015 Nov; 17(6):661-8.
    View in: PubMed
    Score: 0.042
  46. Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. Leuk Res. 2015 Oct; 39(10):1034-40.
    View in: PubMed
    Score: 0.042
  47. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.